Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AC Immune SA

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
AC Immune SA Appoints New Chief Medical Officer
From AC Immune SA
Via GlobeNewswire
Tickers ACIU
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.